NR4A receptors, including NUR77 (NR4A1), NURR1 (NR4A2) and NOR-1 (NR4A3), form a family of nuclear receptors that act as transcription factors to regulate many physiological and pathological processes such as cell cycle and apoptosis, lipid metabolism, inflammation, carcinogenesis, vascular and neuronal functions. In the absence of known endogenous ligand modulating their physiological functions, the NR4A family remains a class of orphan receptors. However, several post-translational modifications (PTMs), including SUMOylation, have been shown to regulate the expression and/or activity of these receptors. Addition of Small Ubiquitin-like MOdifier (SUMO) proteins is a dynamic and reversible enzymatic process that regulates multiple essential functions of proteins, including nuclear receptors. This review aims at summarizing what is known about the impact of SUMOylation on NR4A family member transcriptional activities and physiological functions.

NR4A 受体，包括 NUR77 (NR4A1)、NURR1 (NR4A2) 和 NOR-1 (NR4A3)，形成一个核受体家族，作为转录因子调节许多生理和病理过程，如细胞周期和细胞凋亡、脂质代谢、炎症、致癌作用、血管和神经元功能。在不存在调节其生理功能的已知内源性配体的情况下，NR4A 家族仍然是一类孤儿受体。然而，包括 SUMOylation 在内的几种翻译后修饰 (PTM) 已被证明可以调节这些受体的表达和/或活性。添加小型泛素样修饰因子 (SUMO) 是一种动态且可逆的酶促过程，可调节蛋白质的多种基本功能，包括核受体。